Genetics & Genomics Frontiers — 2026-05-08
This week in genetics and genomics, a new AI tool demonstrated it can reconstruct genetic ancestry from DNA mutation patterns in minutes, matching top statistical methods. Industry news from GenomeWeb reveals significant market movements, including GeneDx stock falling after Q1 disappointments and Tempus AI posting strong 36% revenue growth. A CRISPR-Cas9 Phase 1 trial targeting ANGPTL3 published in NEJM showed substantial reductions in the protein at higher doses, with a promising safety profile.
Genetics & Genomics Frontiers — 2026-05-08
Key Highlights
AI Tool Rewrites Ancestry Analysis Speed Record
An AI tool built on a modified GPT-2 language model can now rapidly reconstruct genetic ancestry by analyzing mutation patterns in DNA, matching the accuracy of leading statistical methods while operating significantly faster. The breakthrough could accelerate large-scale population genomics studies and consumer ancestry applications alike.
CRISPR-Cas9 Targets Cardiovascular Risk Gene in Phase 1 Trial
A Phase 1 trial published this week in the New England Journal of Medicine assessed CRISPR-Cas9 gene editing targeting ANGPTL3 — a gene linked to elevated triglycerides and cardiovascular disease risk. Results showed that at doses of 0.7 mg/kg and 0.8 mg/kg, ANGPTL3 levels fell by approximately 79.7% and 73.2% from baseline, respectively. The editing was associated with few adverse events. The trial was funded by CRISPR Therapeutics and registered with the Australia New Zealand Clinical Trials Registry.
Genomics Industry: Market Movements This Week
GenomeWeb reported multiple significant industry developments this week:
- GeneDx stock tumbled after Q1 revenue came in $12 million below internal expectations, prompting a reassessment of its 2026 guidance, which was described as previously "too aggressive."
- Tempus AI reported a 36% spike in Q1 revenue, with diagnostics revenue growing 35% year over year to $261.1 million, driven by 28% oncology volume growth, and raised its full-year guidance.
- BillionToOne Q1 revenue jumped 84% on a spike in prenatal clinical testing.
- Twist Bioscience agreed to settle a class action lawsuit for $17.1 million while simultaneously raising its full-year guidance to between $442 million and $447 million on strong Q2 results of $110.7 million.
- Stanford University spinout Pumpkinseed raised $20 million to advance protein sequencing technology.
- Neogen announced it will sell its animal genomics business to Zoetis for $160 million.
Genotype-Guided Antidepressant Prescribing Shows Promise
New research highlighted by GenomeWeb found that a genotype-guided approach to SSRI prescription led to increased depression remission rates at six months compared to standard prescribing — a notable step forward for pharmacogenomics in mental health.
Genomics and AI: Biotech Convergence Accelerates
A new wave of biotech advancements is focusing on converging personalized medicine with CRISPR gene editing, according to GeneOnline. Companies are exploring platforms that combine AI-driven target identification with therapeutic gene editing approaches.
Field Note: J. Craig Venter Dies at Age 79
Genomics pioneer J. Craig Venter, best known for leading Celera Genomics in a landmark competition with the International Human Genome Sequencing Consortium during the Human Genome Project, died this week at age 79, according to GenomeWeb.
Analysis
The most significant development this week is the NEJM-published Phase 1 data on CRISPR-Cas9 targeting ANGPTL3. The steep, dose-dependent reductions — nearly 80% at the highest doses tested — with a clean early safety profile position this therapy as a potentially transformative intervention for patients with refractory hyperlipidemia or cardiovascular risk who cannot adequately manage ANGPTL3-driven triglyceride elevation through existing drugs.
The trial's funding by CRISPR Therapeutics signals continued commercial investment in cardiovascular gene editing, a space that has attracted significant competition. If safety holds across broader patient populations and longer follow-up, this approach could challenge the dominance of conventional lipid-lowering therapies.
The AI-ancestry reconstruction story also deserves attention: speed breakthroughs in population genetics analysis could meaningfully lower the cost and turnaround time for large biobank studies, potentially enabling real-time genomic epidemiology.
What to Watch
- CRISPR Therapeutics' ANGPTL3 program will need to advance to larger Phase 2/3 cohorts to confirm the early safety and efficacy signals from the Phase 1 NEJM data. Watch for trial expansion announcements.
- GeneDx has signaled a reassessment of its 2026 revenue guidance following the Q1 miss; updated guidance and management commentary will be key for the genomics diagnostics sector.
- Tempus AI's Alzheimer's testing collaboration with Quanterix is a partnership to follow, as multimodal biomarker strategies combining genomics and protein biomarkers gain traction in neurodegenerative disease research.
- Fox Chase Cancer Center and Labcorp's clinical trial using Plasma Detect Genome MRD (minimal residual disease) testing in non-small cell lung cancer (NSCLC) is one to monitor for early data readouts.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
